作者
Parambir S Dulai, Siddharth Singh, Niels Vande Casteele, Joseph Meserve, Adam Winters, Shreya Chablaney, Satimai Aniwan, Preeti Shashi, Gursimran Kochhar, Aaron Weiss, Jenna L Koliani-Pace, Youran Gao, Brigid S Boland, John T Chang, David Faleck, Robert Hirten, Ryan Ungaro, Dana Lukin, Keith Sultan, David Hudesman, Shannon Chang, Matthew Bohm, Sashidhar Varma, Monika Fischer, Eugenia Shmidt, Arun Swaminath, Nitin Gupta, Maria Rosario, Vipul Jairath, Leonardo Guizzetti, Brian G Feagan, Corey A Siegel, Bo Shen, Sunanda Kane, Edward V Loftus Jr, William J Sandborn, Bruce E Sands, Jean-Frederic Colombel, Karen Lasch, Charlie Cao
发表日期
2020/12/1
期刊
Clinical Gastroenterology and Hepatology
卷号
18
期号
13
页码范围
2952-2961. e8
出版商
WB Saunders
简介
Background & Aims
We created and validated a clinical decision support tool (CDST) to predict outcomes of vedolizumab therapy for ulcerative colitis (UC).
Methods
We performed logistic regression analyses of data from the GEMINI 1 trial, from 620 patients with UC who received vedolizumab induction and maintenance therapy (derivation cohort), to identify factors associated with corticosteroid-free remission (full Mayo score of 2 or less, no subscore above 1). We used these factors to develop a model to predict outcomes of treatment, which we called the vedolizumab CDST. We evaluated the correlation between exposure and efficacy. We validated the CDST in using data from 199 patients treated with vedolizumab in routine practice in the United States from May 2014 through December 2017.
Results
Absence of exposure to a tumor necrosis factor (TNF) antagonist (+3 points), disease duration of 2 y or more (+3 …
学术搜索中的文章
PS Dulai, S Singh, NV Casteele, J Meserve, A Winters… - Clinical Gastroenterology and Hepatology, 2020